Viramidine: Final Phase IIb data

Final data from the open-label, U.S. Phase IIb Study 204 trial in 275 treatment-naïve patients showed that 20, 25 or 30 mg/kg Viramidine plus PegIntron peginterferon alfa-2b for 48 weeks led to a sus...